ReviewClinical kidney journal2025
Advanced chronic kidney disease coexisting with heart failure: navigating patients' management.
Review in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Acute Heart Failure Across the Ejection Fraction Spectrum: Phenotypes, Management, and Outcomes From Nationwide KorHF III Registry.International journal of heart failure · 2026Article
- Effect of inspiratory muscle training in patients with chronic heart failure: a systematic review and meta-analysis of randomized controlled trials.Journal of thoracic disease · 2025Article
- Targeting Obesity for Heart Failure.European cardiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) and heart failure (HF) are interrelated, mutually exacerbating conditions. HF in patients with moderate to severe CKD poses unique clinical problems. Indeed, considerations related to specific concomitant derangements, such as vascular calcification, inflammation, and proteinuria, inform and demand personalized treatment strategies. Pharmacological interventions, including renin-angiotensin system antagonists, sodium-glucose cotransporter 2 (SGLT2) inhibitors and novel mineralocorticoid receptor blockers are valuable in managing these complex conditions, although frequently difficult or impossible to use in advanced kidney disease. Precision medicine, innovative treatments, and the incorporation of digital health tools, artificial intelligence, remote monitoring, and advanced imaging techniques into patient care are redesigning the scenario of HF associated with CKD. AI-driven predictive analytics for early detection of decompensation, telemedicine for remote consultations, and electronic health records with decision-support systems. These innovations enhance personalized treatment, improve early intervention, and optimize disease management, ultimately leading to better outcomes for patients with HF and CKD. Collaborative care models are being implemented and evaluated to advance the management of such conditions. Thus, the integration of novel therapeutic approaches and personalized medicine holds promise for improving patient outcomes, while ongoing research is essential to enabling innovation in this area. Here we review the current management of concomitant kidney disease and HF, highlighting areas for proposed future refinements.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.